FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387033706> ?p ?o ?g. }

• W4387033706 abstract "Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) adults failing their current antiretroviral regimen. Here, we report 240-week efficacy and safety of fostemsavir + OBT in adults with multidrug-resistant human immunodeficiency virus (HIV)-1 in BRIGHTE.Heavily treatment-experienced adults failing their current regimen entered the randomized cohort (RC; 1-2 fully active antiretrovirals available) or non-randomized cohort (NRC; no fully active antiretrovirals available) and received open-label fostemsavir + OBT (starting Day 8 in RC and Day 1 in NRC). Endpoints included proportion with virologic response (HIV-1 RNA < 40 copies/mL, Snapshot), immunologic efficacy, and safety.At Week 240, 45% and 22% of the RC and NRC, respectively, had virologic response (Snapshot); 7% of the RC and 5% of the NRC had missing data due to coronavirus disease 2019 (COVID-19)-impacted visits. In the observed analysis, 82% of the RC and 66% of the NRC had virologic response. At Week 240, mean change from baseline in CD4+ T-cell count was 296 cells/mm3 (RC) and 240 cells/mm3 (NRC); mean CD4+/CD8+ ratio increased between Weeks 96 and 240 (RC 0.44 to 0.60; NRC 0.23 to 0.32). Between Weeks 96 and 240, four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm3). COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident.Through ~5 years, fostemsavir + OBT demonstrated durable virologic and immunologic responses with no new safety concerns between Weeks 96 and 240, supporting this regimen as a key therapeutic option for HTE people with multidrug-resistant HIV-1.ClinicalTrials.gov, NCT02362503." @default.
• W4387033706 created "2023-09-27" @default.
• W4387033706 creator A5008437170 @default.
• W4387033706 creator A5011786542 @default.
• W4387033706 creator A5017386021 @default.
• W4387033706 creator A5019989906 @default.
• W4387033706 creator A5020583927 @default.
• W4387033706 creator A5024560316 @default.
• W4387033706 creator A5029461319 @default.
• W4387033706 creator A5030704236 @default.
• W4387033706 creator A5045360426 @default.
• W4387033706 creator A5051200837 @default.
• W4387033706 creator A5067253427 @default.
• W4387033706 creator A5067600985 @default.
• W4387033706 creator A5077342020 @default.
• W4387033706 creator A5083402039 @default.
• W4387033706 creator A5083690472 @default.
• W4387033706 creator A5088973456 @default.
• W4387033706 date "2023-09-26" @default.
• W4387033706 modified "2023-09-27" @default.
• W4387033706 title "Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1" @default.
• W4387033706 cites W1967284000 @default.
• W4387033706 cites W1998353416 @default.
• W4387033706 cites W2038194012 @default.
• W4387033706 cites W2046246036 @default.
• W4387033706 cites W2054610125 @default.
• W4387033706 cites W2077374442 @default.
• W4387033706 cites W2092848363 @default.
• W4387033706 cites W2103115327 @default.
• W4387033706 cites W2107249411 @default.
• W4387033706 cites W2114964028 @default.
• W4387033706 cites W2116146956 @default.
• W4387033706 cites W2131508360 @default.
• W4387033706 cites W2147308876 @default.
• W4387033706 cites W2600604146 @default.
• W4387033706 cites W2750272252 @default.
• W4387033706 cites W2775178549 @default.
• W4387033706 cites W2887987288 @default.
• W4387033706 cites W3002036436 @default.
• W4387033706 cites W3013800457 @default.
• W4387033706 cites W3034821186 @default.
• W4387033706 cites W3097331958 @default.
• W4387033706 cites W3128190569 @default.
• W4387033706 cites W3136863660 @default.
• W4387033706 cites W3184902330 @default.
• W4387033706 cites W3213196037 @default.
• W4387033706 cites W4200222846 @default.
• W4387033706 cites W4221132868 @default.
• W4387033706 cites W4289878451 @default.
• W4387033706 doi "https://doi.org/10.1007/s40121-023-00870-6" @default.
• W4387033706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37751019" @default.
• W4387033706 hasPublicationYear "2023" @default.
• W4387033706 type Work @default.
• W4387033706 citedByCount "0" @default.
• W4387033706 crossrefType "journal-article" @default.
• W4387033706 hasAuthorship W4387033706A5008437170 @default.
• W4387033706 hasAuthorship W4387033706A5011786542 @default.
• W4387033706 hasAuthorship W4387033706A5017386021 @default.
• W4387033706 hasAuthorship W4387033706A5019989906 @default.
• W4387033706 hasAuthorship W4387033706A5020583927 @default.
• W4387033706 hasAuthorship W4387033706A5024560316 @default.
• W4387033706 hasAuthorship W4387033706A5029461319 @default.
• W4387033706 hasAuthorship W4387033706A5030704236 @default.
• W4387033706 hasAuthorship W4387033706A5045360426 @default.
• W4387033706 hasAuthorship W4387033706A5051200837 @default.
• W4387033706 hasAuthorship W4387033706A5067253427 @default.
• W4387033706 hasAuthorship W4387033706A5067600985 @default.
• W4387033706 hasAuthorship W4387033706A5077342020 @default.
• W4387033706 hasAuthorship W4387033706A5083402039 @default.
• W4387033706 hasAuthorship W4387033706A5083690472 @default.
• W4387033706 hasAuthorship W4387033706A5088973456 @default.
• W4387033706 hasBestOaLocation W43870337061 @default.
• W4387033706 hasConcept C126322002 @default.
• W4387033706 hasConcept C142462285 @default.
• W4387033706 hasConcept C168563851 @default.
• W4387033706 hasConcept C197934379 @default.
• W4387033706 hasConcept C203014093 @default.
• W4387033706 hasConcept C2781413609 @default.
• W4387033706 hasConcept C3013748606 @default.
• W4387033706 hasConcept C535046627 @default.
• W4387033706 hasConcept C71924100 @default.
• W4387033706 hasConcept C72563966 @default.
• W4387033706 hasConceptScore W4387033706C126322002 @default.
• W4387033706 hasConceptScore W4387033706C142462285 @default.
• W4387033706 hasConceptScore W4387033706C168563851 @default.
• W4387033706 hasConceptScore W4387033706C197934379 @default.
• W4387033706 hasConceptScore W4387033706C203014093 @default.
• W4387033706 hasConceptScore W4387033706C2781413609 @default.
• W4387033706 hasConceptScore W4387033706C3013748606 @default.
• W4387033706 hasConceptScore W4387033706C535046627 @default.
• W4387033706 hasConceptScore W4387033706C71924100 @default.
• W4387033706 hasConceptScore W4387033706C72563966 @default.
• W4387033706 hasLocation W43870337061 @default.
• W4387033706 hasLocation W43870337062 @default.
• W4387033706 hasOpenAccess W4387033706 @default.
• W4387033706 hasPrimaryLocation W43870337061 @default.
• W4387033706 hasRelatedWork W2096903645 @default.
• W4387033706 hasRelatedWork W2150621792 @default.
• W4387033706 hasRelatedWork W2315085516 @default.
• W4387033706 hasRelatedWork W2603773853 @default.

• next